Alloantibodies in von Willebrand disease

Blood

Volumn 122, Issue 5, 2013, Pages 636-640

  James, Paula D ^a   Lillicrap, David ^a   Mannucci, Pier M ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8;

ADVERSE OUTCOME; ANAPHYLAXIS; ANTIBODY DETECTION; BLEEDING; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOLECULAR PATHOLOGY; NONSENSE MUTATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TEMPERATURE DEPENDENCE; VON WILLEBRAND DISEASE; BLOOD; GENETICS; IMMUNOLOGY; METABOLISM;

FACTOR VIII; HUMANS; ISOANTIBODIES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84886395616     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-462085     Document Type: Review

References (55)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987; 69(2): 454-459. (Pubitemid 17022013)
2. Werner EJ, Broxson EH, Tucker E.L., et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993; 123(6): 893-898. (Pubitemid 23353251)
3. Bowman M, Hopman WM, Rapson D, et al. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010; 8(1): 213-216.
4. Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia. 1999; 5(3): 223-231, discussion 222.
5. Sadler JE, Budde U, Eikenboom JCJ, et al.; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4(10): 2103-2114. (Pubitemid 44403432)
6. Sarji KE, Stratton RD, Wagner R.H., et al. Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc Natl Acad Sci USA. 1974; 71(8): 2937-2941.
7. Stratton RD, Wagner RH, Webster W.P., et al. Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc Natl Acad Sci USA. 1975; 72(10): 4167-4171.
8. Egberg N, Blombäck M. On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand's disease. Thromb Res. 1976; 9(5): 527-531.
9. Mannucci PM, Meyer D, Ruggeri Z.M., et al. Precipitating antibodies in von Willebrand's disease. Nature. 1976; 262(5564): 141-142.
10. Mannucci PM, Tamaro G, Narchi G., et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol. 1987; 39(5): 467-470. (Pubitemid 18002930)
11. Bergamaschini L, Mannucci PM, Federici A.B., et al. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995; 125(3): 348-355.
12. Mannucci PM, Mari D. Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease. Prog Clin Biol Res. 1984; 150: 109-122.
13. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol. 1995; 386: 87-92.
14. Iorio A, Oliovecchio E, Morfini M., et al.; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia. 2008; 14(3): 444-453. (Pubitemid 351638730)
15. Lusher JM, Arkin S, Abildgaard C.F., et al.; Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med. 1993; 328(7): 453-459. (Pubitemid 23056434)
16. Dimichele D, Rivard G, Hay C., et al. Inhibitors in haemophilia: clinical aspects. Haemophilia. 2004; 10(SUPPL. 4): 140-145. (Pubitemid 40045433)
17. Hay CRM, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6): 1335-1344.
18. Helmer RE III, Alperin JB, Yunginger JW, et al. Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia. Am J Med. 1980; 69(6): 953-957. (Pubitemid 11199871)
19. Bove JR, McIntosh S. Anaphylactic reaction to purified anti-hemophilic factor concentrate. Transfusion. 1988; 28(6): 603.
20. Shopnick RI, Kazemi M, Brettler D.B., et al. Anaphylaxis after treatment with recombinant factor VIII. Transfusion. 1996; 36(4): 358-361. (Pubitemid 26141065)
21. Kamiya T, Takahashi I, Saito H. Retrospective study of inhibitor formation in Japanese hemophiliacs. Int J Hematol. 1995; 62(3): 175-181.
22. Sultan Y; French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992; 67(6): 600-602.
23. Franchini M, Lippi G, Montagnana M., et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis. 2009; 20(4): 225-229.
24. Thorland EC, Drost JB, Lusher J.M., et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999; 5(2): 101-105. (Pubitemid 29182528)
25. Zhang ZP, Lindstedt M, Falk G., et al. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet. 1992; 51(4): 850-858.
26. Ruggeri ZM, Ciavarella N, Mannucci P.M., et al. Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases. J Lab Clin Med. 1979; 94(1): 60-75. (Pubitemid 10213898)
27. Shelton-Inloes B.B., Chehab FF, Mannucci P.M., et al. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987; 79(5): 1459-1465. (Pubitemid 17099650)
28. Bloom AL, Peake IR, Furlong R.A., et al. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand's disease and inhibitor. Thromb Res. 1979; 16(5-6): 847-852. (Pubitemid 10207513)
29. Maragall S, Castillo R, Ordinas A., et al. Inhibition of Willebrand factor in von Willebrand disease. Thromb Res. 1979; 14(2-3): 495-500. (Pubitemid 9150762)
30. Baronciani L, Cozzi G, Canciani M.T., et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis. 2003; 30(3): 264-270. (Pubitemid 36539427)
31. Mohl A, Marschalek R, Masszi T., et al. An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary. J Thromb Haemost. 2008; 6(10): 1729-1735.
32. Mohl A, Boda Z, Jager R., et al. Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population. J Thromb Haemost. 2011; 9(5): 945-952.
33. Berntorp E, Peake I, Budde U., et al. von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia. 2012; 18(SUPPL. 6): 1-13.
34. van Genderen P.J., Vink T, Michiels J.J., et al. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood. 1994; 84(10): 3378-3384. (Pubitemid 24352900)
35. Tiede A, Priesack J, Werwitzke S., et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost. 2008; 6(4): 569-576. (Pubitemid 351404923)
36. Stewart MW, Etches WS, Shaw A.R., et al. vWf inhibitor detection by competitive ELISA. J Immunol Methods. 1997; 200(1-2): 113-119. (Pubitemid 27035693)
37. Siaka C, Rugeri L, Caron C., et al. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003; 9(3): 303-308. (Pubitemid 36622033)
38. Tout H, Obert B, Houllier A., et al. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemost. 2000; 83(2): 274-281. (Pubitemid 30093232)
39. López-Fernández MF, Martin R, López-Berges C, et al. Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood. 1988; 72(1): 116-120.
40. Batlle J, Lourés E, Vila P., et al. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction. Ann Hematol. 1997; 75(3): 111-115. (Pubitemid 27453913)
41. Abshire TC, Federici AB, Alvarez M.T., et al. Prophylaxis in severe forms of von Willebrand disease: results from the von Willebrand's Disease Prophylaxis Network (VWD PN). Haemophilia. 2013; 19(1): 76-78.
42. Halimeh S, Krümpel A, Rott H., et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost. 2011; 105(4): 597-604.
43. Franchini M, Gandini G, Giuffrida A., et al. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia. 2008; 14(3): 645-646. (Pubitemid 351638764)
44. Ciavarella N, Schiavoni M, Valenzano E., et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis. 1996; 26(SUPPL. 1): 150-154.
45. Pergantou H, Xafaki P, Adamtziki E., et al. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia. 2012; 18(3): e66-e67.
46. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci USA. 1995; 92(7): 2428-2432.
47. Sultan Y, Bouma BN, de Graaf S, et al. Factor VIII related antigen in platelets of patients with Von Willebrand's disease. Thromb Res. 1977; 11(1): 23-30. (Pubitemid 8143378)
48. Suiter TM, Mannucci PM, Kempton C.L., et al. Detection of non inhibitory binding antibodies to von Willebrand factor affecting the clearance of VWF:Ag in von Willebrand disease. Blood (ASH Annual Meeting Abstracts). 2011; 118(21): 2275.
49. Ngo KY, Glotz VT, Koziol J.A., et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA. 1988; 85(8): 2753-2757.
50. Shoa'i I, Lavergne JM, Ardaillou N, et al. Heterogeneity of von Willebrand's disease: study of 40 Iranian cases. Br J Haematol. 1977; 37(1): 67-83. (Pubitemid 8210506)
51. Lenk H, Weissbach G, Domula M. An inhibitor in the Willebrand- Jürgens syndrome and its effect on the factor VIII molecule properties [in German]. Folia Haematol (Frankf). 1978; 105(6): 826-834. (Pubitemid 9099530)
52. Peake IR, Liddell MB, Moodie P, et al. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood. 1990; 75(3): 654-661. (Pubitemid 20069205)
53. Mancuso DJ, Tuley EA, Castillo R, et al. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors. Thromb Haemost. 1994; 72(2): 180-185. (Pubitemid 24251276)
54. Miller CH, Bussel J, Hilgartner M. Characteristics of inhibitors in severe von Willebrand's disease. Thromb Haemost. 1983; 50(34).
55. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000; 111(4): 1236-1239. (Pubitemid 32104944)